Category News

ICVS Retreat 2024

More than 170 participants attended the ICVS Retreat 2024 at the Monastery of Tibães in Braga, between the 4th and 5th of July.  The program included presentations, debates, poster sessions, well-being and team building activities.

Read MoreICVS Retreat 2024

Study confirms the impact of aspergillosis on the prognosis of critically ill patients with viral pneumonia

Researchers from ICVS published a study in the American Journal of Respiratory and Critical Care Medicine, which assesses the influence of the lung microbiota on the incidence and clinical course of patients diagnosed with influenza-associated aspergillosis (IAPA) or COVID-19 (CAPA), or bacterial superinfections.

Read MoreStudy confirms the impact of aspergillosis on the prognosis of critically ill patients with viral pneumonia

ICVS researchers show that “40% of patients with Alzheimer’s disease suffer from psychosis and identifies affected areas of the brain”

A team of researchers from ICVS recently published an article in the journal “Neurobiology of Aging” that addresses how the presence of psychosis indicates a more negative prognosis and greater cognitive decline in patients diagnosed with the disease of Alzheimer's.

Read MoreICVS researchers show that “40% of patients with Alzheimer’s disease suffer from psychosis and identifies affected areas of the brain”

ICVS collaborates in first study on the prevalence of asthma in Portugal: more than 570 thousand people have the disease

More than 570,000 adults live with asthma in Portugal, a disease that has a prevalence of 7.1%. Of these thousands of people, almost seven in 10 (68%) do not have their disease under control, show data from “EPI-ASTHMA - Prevalence and characterization of people with asthma, according to the severity of the disease, in Portugal”, a study developed in collaboration by ICVS, CINTESIS of the University of Porto and AstraZeneca Portugal.

Read MoreICVS collaborates in first study on the prevalence of asthma in Portugal: more than 570 thousand people have the disease

Compound that aids in the digestion of fatty foods within the intestine demonstrates potential as a treatment for a rare brain disorder

In a work, recently published in the Journal of Clinical Investigation, researchers at the Life and Health Science Research Institute (ICVS) at the University of Minho, in Portugal, used animal models of spinocerebellar ataxia type 3 or Machado-Joseph disease (SCA3/MJD) to test a promising drug: the compound tauroursodeoxycholic acid (TUDCA for short).

Read MoreCompound that aids in the digestion of fatty foods within the intestine demonstrates potential as a treatment for a rare brain disorder